DepoMed, Inc. (NASDAQ:DEPO)

CAPS Rating: 4 out of 5

A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.

Recs

3
Player Avatar yellowear (< 20) Submitted: 5/9/2010 12:29:14 PM : Outperform Start Price: $2.45 DEPO Score: +104.35

When all the bad news is out and the stock has oversold below $2.50, that's when I bought with real money and expect in 5 years to be more than a 5 bagger.

Just about perfect trade!

Featured Broker Partners


Advertisement